Top Story Today
The Cancer Vaccine That's Never the Same Twice Just Made History
No individualized cancer vaccine has yet completed a Phase 3 trial, but Moderna and Merck's personalized mRNA vaccine just moved closer than any before. Built from scratch using each patient's tumor DNA, the vaccine encodes up to 34 tumor-specific mutations per patient, turning the immune system into a precision hunting squad. The Phase 2b data showed a 49% reduction in recurrence risk that held up at five years, and a Phase 3 trial is now fully enrolled to confirm the effect at scale. Analysts are calling it a make-or-break moment for Moderna's post-COVID identity.
Why it matters: This is the strongest clinical validation yet that personalized mRNA cancer vaccines actually work in practice, not just in theory. If the Phase 3 trial confirms Phase 2b results and the approach expands into kidney, bladder, and lung cancers as expected, it could reshape post-surgical oncology and open a multi-billion-dollar market category that didn't exist five years ago.
Read more →Deals and M&A
Lilly Paid $2.4 Billion for a Circle. Seriously.
Eli Lilly is acquiring Orna Therapeutics for up to $2.4 billion, betting that circular RNA can reprogram immune cells inside the body without extracting them first. If mRNA is a paper airplane, circRNA is a Frisbee: harder for enzymes to destroy, longer-lasting protein production, fewer immune alarm bells. It's one of several major genetic medicine deals Lilly has made this year, signaling deep conviction that immunology (not just obesity drugs) will drive its next growth chapter.
Read more →Argenx Drops $2.2B on a Company Most People Haven't Heard Of
Argenx, the company behind $4.2 billion-a-year VYVGART, is paying $2.2 billion (an 86% premium) for Forte Biosciences and its lead drug targeting CD122 in autoimmune diseases like celiac and vitiligo. It's a deliberate move to break free from a single-mechanism identity, with celiac disease alone representing virgin territory: no approved drug treatment exists.
Read more →Sandoz Goes Shopping in Shanghai for Biosimilar Firepower
Sandoz signed a deal worth up to $322 million with Shanghai Henlius covering up to 10 biosimilar assets, with initial focus on copycats of Erbitux, Repatha, and Benlysta, pushing its pipeline to 39 assets. With a massive wave of biologic patent cliffs approaching, the Swiss giant is building an army and using China's deep bench of developers as its pipeline engine.
Read more →Clinical and Regulatory
Tagrisso's Second Act: Blocking Cancer's Favorite Escape Route
The Phase 3 SAFFRON trial showed that adding Hutchmed's Orpathys to AstraZeneca's Tagrisso significantly extended both progression-free and overall survival in lung cancer patients whose tumors developed MET-driven resistance. It's the first Phase 3 survival data for a biomarker-directed, all-oral combo that beats chemotherapy in this setting.
Read more →A Pill That Tricks Your Body Into Thinking It Just Worked Out
Enveda's ENV-308 mimics lac-phe, the molecule your body releases after hard exercise to suppress hunger. Phase 1 data in 88 volunteers showed clean tolerability, no GI issues (unlike GLP-1s), and a reduction in leptin. The clever angle: it's not competing with Ozempic for weight loss, it's targeting the massive problem of weight regain after patients stop taking GLP-1 drugs.
Read more →The Only Syphilis Drug for Pregnant Women Just Got Pulled
Pfizer recalled multiple lots of Bicillin L-A, the only drug approved to treat syphilis during pregnancy, after finding particulates during inspection. The supply was already in shortage, congenital syphilis cases are up 700% since 2015, and there is literally no alternative for pregnant patients. One company, one factory, one drug.
Read more →The FDA Just Asked the Public How to Regulate AI Doctors
With AI medical device authorizations rising sharply since 2023, the FDA released a discussion paper asking how generative AI devices should be regulated. The comment period runs until October 19, covering risk frameworks, premarket testing, postmarket monitoring, and the thorny question of foundation models that can hallucinate.
Read more →Science and Markets
A Nobel Laureate Thinks He Can Simulate an Entire Cell
David Baker's GenBio AI unveiled AIDO Cell, an AI system pretrained on a large corpus of human cell data that simulates biology from DNA to whole-cell behavior. The catch: it currently supports just two cell lines. Think first iPhone; clearly the future, but it couldn't copy and paste yet.
Read more →CSL Posted a $2.6B Loss. Its Stock Had Its Best Day in 25 Years.
CSL shares surged 18% after annual earnings beat expectations, despite a headline $2.6 billion net loss driven by restructuring charges. The real signal: operating cash flow stayed healthy at $3.5 billion, management called the worst of its "reset year" over, and a fresh A$1.1 billion buyback told investors the bleeding has stopped. The plasma giant's recovery sends a bullish signal across the entire blood-products sector.
Read more →Eikon Raised $381M in Its IPO. Wall Street Shrugged.
Eikon Therapeutics raised $381 million in an upsized Nasdaq IPO, then watched shares open 5.3% below the offer price. The company has spent over $1.1 billion building a molecular microscopy platform with four clinical-stage cancer drugs but no approvals yet. Analyst coverage is split between Overweight and Underperform, making it a Rorschach test for biotech investors.
Read more →